|
Results of joint call
Background
Contact |
|
Background of the joint call
The three Public Private Partnerships CTMM, TI Pharma and BMM all
focus on the translations of research findings to proof of concept
for new products and services in healthcare. Each of these 'Top
Institutes' has its own special focus. Improved molecular diagnosis
and imaging in CTMM, new medicines in TI Pharma, and new
biomaterials in BMM. The common denominator that characterizes these
programs is personalized
medicine, - treatment tailored for the individual patient
to optimize efficacy, outcomes and patient comfort.
The deliverables of the research programs will contribute to
personalized treatment, minimally invasive therapeutic
interventions, an improved performance of existing and new drugs and
better monitoring and staging of the regression of disease.
Many of these innovations will rely on the simultaneous applications
of technology developed in the three different programs. For
example, the discovery of biomarkers of heart failure and arrhythmia
(CTMM) will provide better patient triaging to select candidate stem
cell therapies (BMM). Molecular Imaging and the use of companion
diagnostics (CTMM) will greatly enhance the efficacy of targeted
drugs (TI Pharma). New scaffolds or nanoparticles (BMM) may be used
for the local release and targeting delivery of high concentrations
of medicines (TI Pharma).
Close interactions between the different disciplines in the three
top institutes will be able to realize these innovations.
Therefore, CTMM, TI Pharma and BMM initiated a call for proposals
for research focused on the interface of the three institutes:
Imaging Guided and Targeted Drug Delivery. The projects emerging
from this call for proposals represent the first example of an
interdisciplinary public-private consortium that encompasses
competencies from all three institutes. Projects are performed by
academia and industry in close cooperation. This model will provide
a roadmap for a more cohesive, interdisciplinary approach in the
Dutch life sciences.
|
